TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03448848
Drug: sterile normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline in a volume equal to the study drug
Study: NCT02489123
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01128894
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
Study: NCT00824811
Drug: Cyclosporine Eye Drops (Restasis)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
Study: NCT00824811
Drug: Lubricant Eye Drops (Refresh Endura™)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
Study: NCT00824811
Drug: Fluorometholone Eye Drops (FML Forte®)
Normalized name: fluorometholone Ophthalmic Suspension [FML Forte Liquifilm]
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®.
Study: NCT00938860
Drug: cyclosporin (Neoral)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
Study: NCT00938860
Drug: tacrolimus (Prograf)
Normalized name: TACROLIMUS (PROGRAF) 1MG CAP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
Study: NCT03741933
Drug: Apremilast 30mg
Normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg tablet
Study: NCT01189448
Drug: Pyrimethamine/Sulfadiazine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy.
Study: NCT01189448
Drug: Spiramycine
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures
Study: NCT02265510
Drug: INCB052793
Normalized name: INCB052793
DrugBank: INCB052793 (DB17567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
Study: NCT03645603
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT01084161
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg IV once per day
Study: NCT01084161
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg IV once per day
Study: NCT01084161
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg IV once per day
Study: NCT01084161
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg IV once per day
Study: NCT01084161
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 10-15 mg IV once per day
Study: NCT01084161
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg IV once per day
Study: NCT01739517
Drug: Omegaven Therapy
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
Study: NCT00117611
Drug: Anti-IgE antibody omalizumab or placebo
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given subcutaneously oce or twice monthly depending on dose
Study: NCT03940469
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml normal saline
Study: NCT03940469
Drug: Dexamethasone Injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg dexamethasone
Study: NCT03758287
Drug: CT053PTSA
Normalized name: Ct053ptsa free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03758287
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00153517
Drug: oral versus vaginal metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00195507
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02265510
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administered orally at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib administered intravenously at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide administered orally at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: INCB052793
Normalized name: INCB052793
DrugBank: INCB052793 (DB17567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
Study: NCT02265510
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide administered orally at the protocol-specified dose and frequency.
Study: NCT02265510
Drug: INCB050465
Normalized name: INCB050465
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
Study: NCT02340455
Drug: Pregabalin_male
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150mg bid 1day Men
Study: NCT02340455
Drug: Pregabalin_female
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150mg bid 1day Women
Study: NCT00380900
Drug: AGG-523
Normalized name: AGG-523
DrugBank: AGG-523 (DB15460)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02353780
Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
Study: NCT02353780
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept; SQ; specifics to be determined by the treating rheumatologist.
Study: NCT02353780
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab; SQ; specifics determined by the treating rheumatologist.
Study: NCT01357772
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03940469
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 microgram dexmedetomidine
Study: NCT02915835
Drug: Riociguat
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
Study: NCT01217580
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
Study: NCT01217580
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
Study: NCT02844881
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Study: NCT01660295
Drug: Certoparin 3,000 IU Once Daily
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 3,000 IU subcutaneous injection once daily
Study: NCT03794596
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Colourless odourless aqueous solution for infusion at dose of 10mg/kg
Study: NCT03794596
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg tablets
Study: NCT01660295
Drug: Certoparin 3,000 IU Twice a Day
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 3,000 IU subcutaneous injection twice a day
Study: NCT01660295
Drug: Certoparin 8,000 IU Once Daily
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 8,000 IU subcutaneous injection once daily
Study: NCT02843204
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
Study: NCT00144651
Drug: MRA(Tocilizumab)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg/4 weeks for 1 year
Study: NCT04459065
Drug: IRDye800CW-nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
Study: NCT00523042
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target dose titration scheme, injection s.c.
Study: NCT01660295
Drug: Certoparin 8,000 IU Twice a Day
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 8,000 IU subcutaneous injection twice a day
Study: NCT02623153
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 130 mg/m2
Study: NCT02623153
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 of 40 mg/m2
Study: NCT02623153
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 40 mg/m2
Study: NCT03136328
Drug: 68Ga-DOTATOC
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
Study: NCT00779051
Drug: Zolpidem 10mg tablets
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03630341
Drug: Clomiphene Citrate 50mg
Normalized name: CLOMIPHENE CITRATE 50MG TAB
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 50 mg tablets
Study: NCT03630341
Drug: L-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg oral tablet
Study: NCT03794596
Drug: Lansoprazole (Proton Pump Inhibitor)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg capsule
Study: NCT00651209
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
Study: NCT00490880
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00490880
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02168842
Drug: Isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules Isradipine IR, up to 10 mg, taken twice daily
Study: NCT04094012
Drug: isoniazid and rifapentine
Normalized name: Rifapentine
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
Study: NCT02168842
Drug: Placebo (for Isradipine)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar Pill manufactured to look like Isradipine but has no active ingredients
Study: NCT02147353
Drug: Sinecatechins 15% Ointment
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
Study: NCT02745392
Drug: ZP-Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
Study: NCT02949960
Drug: Vehicle Control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Vehicle Gel applied twice daily
Study: NCT02045966
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01306955
Drug: methylorednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
Study: NCT00116142
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
Study: NCT00116142
Drug: Androgen Hormonal Suppression and Radiation
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total Androgen Ablation and external beam radiation therapy
Study: NCT00335543
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00335543
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02823743
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily medication
Study: NCT00989300
Drug: Treatment A - rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study: NCT00989300
Drug: Treatment B - omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
Study: NCT02561455
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral tablet
Study: NCT00125918
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study: NCT04483544
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
Study: NCT00426153
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
Study: NCT02262923
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04483544
Drug: olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PARP inhibitor olaparib 300 mg orally, twice daily (BID)
Study: NCT00615836
Drug: Desmopressin Melt
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
Study: NCT00912691
Drug: CM-AT
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Study: NCT01613118
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, once-daily
Study: NCT04854668
Drug: Anlotinib hydrochloride capsule
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
Study: NCT04854668
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
Study: NCT04854668
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130mg/m2, intravenous drip, on Day 1；